Orphazyme fails trial in muscle wasting disease

Orphazyme's drug arimoclomol has not shown the desired effect in a pivotal phase II/III trial involving 150 patients with inclusion body myositis (IBM).

Photo: Orphazyme/PR

Read this article for free

Register with your E-mail.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

WS Audiology plans to list subsidiary

Privately-owned hearing aid company WS Audiology, which grew out of the merger between Widex and Sivantos, plans to list, which handles online sales.

Further reading

Related articles

Latest news

See all jobs